Current management of non-alcoholic steatohepatitis - PubMed (original) (raw)
Review
. 2020 Feb;40 Suppl 1(Suppl 1):89-95.
doi: 10.1111/liv.14355.
Affiliations
- PMID: 32077609
- PMCID: PMC7654093
- DOI: 10.1111/liv.14355
Review
Current management of non-alcoholic steatohepatitis
Mark D Muthiah et al. Liver Int. 2020 Feb.
Abstract
Non-alcoholic steatohepatitis (NASH) is the most common cause of liver disease in Western populations, and its prevalence is increasing rapidly. It is part of a multisystem disease affecting other organs such as the kidneys, heart and blood vessels, and is closely associated with the components of the metabolic syndrome. Physicians managing patients with NASH should not only focus on the management of NASH, but also on associated comorbidities in individual patients. The approaches to treatment of NASH include either limiting energy surplus alone, or in combination with targeting of downstream pathways of inflammation and fibrosis. In this mini-review, we discuss the currently available treatment options for NASH, as well as those in late-stage clinical trials. We discuss the challenges of managing these patients with a limited number of approved therapies, as well as managing advanced-stage patients with NASH and cirrhosis. We also discuss the specific management of comorbidities in NASH patients, in particular diabetes, hypertension, dyslipidaemia and cardiovascular diseases. Finally, we present the screening protocols for both hepatocellular carcinoma and extrahepatic malignancies in these patients.
Keywords: management; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; treatment.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
- Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E, Paul SB, Kedia S. Dhamija E, et al. Indian J Med Res. 2019 Jan;149(1):9-17. doi: 10.4103/ijmr.IJMR_1456_17. Indian J Med Res. 2019. PMID: 31115369 Free PMC article. Review. - Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma: A Growing Epidemic?
Yopp AC, Choti MA. Yopp AC, et al. Dig Dis. 2015 Sep;33(5):642-7. doi: 10.1159/000438473. Epub 2015 Sep 23. Dig Dis. 2015. PMID: 26398208 - Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S, Kienbacher C, Halilbasic E, Rechling C, Kazemi-Shirazi L, Hofer H, Munda P, Trauner M. Traussnigg S, et al. Dig Dis. 2015;33(4):598-607. doi: 10.1159/000375353. Epub 2015 Jul 6. Dig Dis. 2015. PMID: 26159280 Review. - Therapies in non-alcoholic steatohepatitis (NASH).
Oseini AM, Sanyal AJ. Oseini AM, et al. Liver Int. 2017 Jan;37 Suppl 1(Suppl 1):97-103. doi: 10.1111/liv.13302. Liver Int. 2017. PMID: 28052626 Free PMC article. Review. - Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease.
Chew NWS, Ng CH, Muthiah MD, Sanyal AJ. Chew NWS, et al. Curr Atheroscler Rep. 2022 Jul;24(7):515-532. doi: 10.1007/s11883-022-01027-5. Epub 2022 May 4. Curr Atheroscler Rep. 2022. PMID: 35507280 Review.
Cited by
- Evaluating the therapeutic potential of genetically engineered probiotic Zbiotics (ZB183) for non-alcoholic steatohepatitis (NASH) management via modulation of the cGAS-STING pathway.
Saad M, Ibrahim W, Hasanin AH, Elyamany AM, Matboli M. Saad M, et al. RSC Med Chem. 2024 Sep 13;15(11):3817-36. doi: 10.1039/d4md00477a. Online ahead of print. RSC Med Chem. 2024. PMID: 39290381 - Gypensapogenin A-Liposomes Efficiently Ameliorates Hepatocellular Lipid Accumulation via Activation of FXR Receptor.
Deng Y, Wang J, Wu D, Qin L, He Y, Tan D. Deng Y, et al. Molecules. 2024 Aug 28;29(17):4080. doi: 10.3390/molecules29174080. Molecules. 2024. PMID: 39274927 Free PMC article. - Nano-drug delivery systems (NDDS) in metabolic dysfunction-associated steatotic liver disease (MASLD): current status, prospects and challenges.
Yang Y, Wang X. Yang Y, et al. Front Pharmacol. 2024 Aug 6;15:1419384. doi: 10.3389/fphar.2024.1419384. eCollection 2024. Front Pharmacol. 2024. PMID: 39166109 Free PMC article. Review. - Rapid improvement of hepatic steatosis and liver stiffness after metabolic/bariatric surgery: a prospective study.
Nixdorf L, Hartl L, Ströhl S, Felsenreich DM, Mairinger M, Jedamzik J, Richwien P, Mozayani B, Semmler G, Balcar L, Schwarz M, Jachs M, Dominik N, Bichler C, Trauner M, Mandorfer M, Reiberger T, Langer FB, Bauer DJM, Prager G. Nixdorf L, et al. Sci Rep. 2024 Jul 30;14(1):17558. doi: 10.1038/s41598-024-67415-w. Sci Rep. 2024. PMID: 39080285 Free PMC article. - Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies.
Pramanik S, Pal P, Ray S. Pramanik S, et al. World J Methodol. 2024 Jun 20;14(2):91319. doi: 10.5662/wjm.v14.i2.91319. eCollection 2024 Jun 20. World J Methodol. 2024. PMID: 38983664 Free PMC article. Review.
References
- Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7(2):234–238. - PubMed
- Bray GA, Fruhbeck G, Ryan DH, Wilding JP. Management of obesity. Lancet. 2016;387(10031):1947–1956. - PubMed
- Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829–846. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical